Dopamine D2-like receptor agonists induce penile erection in male rats: Differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus

Behavioural Brain Research

Volumn 225, Issue 1, 2011, Pages 169-176

  Sanna, Fabrizio ^a,b   Succu, Salvatora ^a,b   Hübner, Harald ^c   Gmeiner, Peter ^c   Argiolas, Antonio ^a,b   Melis, Maria Rosaria ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apomorphine; Dopamine agonists; Paraventricular nucleus of the hypothalamus; PD 168,077; Penile erection; Pramipexole; Rat

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; FAUC 365; L 741626; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; PRAMIPEXOLE; RACLOPRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; MALE; MICROINJECTION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; MALE; MICROINJECTIONS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PENILE ERECTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4;

EID: 79960891535     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.07.018     Document Type: Article

References (52)

1. Meisel R.L., Sachs B.D. The physiology of male sexual behavior. The physiology of reproduction 1994, vol. 2:3-96. Raven Press, New York. 2nd edn.
2. McKenna K.E. Some proposals regarding the organization of the central nervous system control of penile erection. Neurosci Biobehav Rev 2000, 24:535-540.
3. Andersson K.E. Pharmacology of penile erection. Pharmacol Rev 2001, 53:417-450.
4. Hull E.M., Meisel R.L., Sachs B.D. Male sexual behavior. Hormones, brain and behavior 2002, 3-137. New York, Academic Press. D.W. Pfaff, A.P. Arnold, A.M. Etgen, S.E. Fahrbach, R.T. Rubin (Eds.).
5. Melis M.R., Argiolas A. Dopamine and sexual behaviour. Neurosci Biobehav Rev 1995, 19:19-38.
6. Melis M.R., Argiolas A. Central oxytocinergic neurotransmission: a drug target for the therapy of psycogenic erectile dysfunction. Curr Drug Targets 2003, 4:55-66.
7. Melis M.R., Succu S., Mascia M.S., Cortis L., Argiolas A. Extra-cellular dopamine increases in the paraventricular nucleus of male rats during sexual activity. Eur J Neurosci 2003, 17:1266-1272.
8. Argiolas A., Melis M.R. The role of oxytocin and the paraventricular nucleus in the sexual behaviour of male mammals. Physiol Behav 2004, 83:309-317.
9. Argiolas A., Melis M.R. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Progr Neurobiol 2005, 76:1-21.
10. Argiolas A. The chemical pharmacology of male erectile dysfunction. Drugs Discov Today: Ther Strategies 2005, 2:31-36.
11. Melis M.R., Argiolas A. Central control of penile erection: a re-visitation of the role of oxytocin and its interaction with dopamine and glutamic acid in male rats. Neurosci Biobehav Rev 2011, 35:939-955.
12. Buijs R.M., Geffard M., Pool C.W., Hoorneman E.M.D. The dopaminergic innervation of the supraoptic and paraventricular nucleus. A light and electron microscopical study. Brain Res 1984, 323:65-72.
13. Lindvall O., Bjorklund A., Skagerberg G. Selective histochemical demonstration of dopamine terminal systems in rat di- and telencephalon: new evidence for dopaminergic innervation of hypothalamic neurosecretory nuclei. Brain Res 1984, 306:19-30.
14. Hull E.M., Bitran D., Pehek E.A., Warner R.K., Band L.C., Holmes G.M. Dopaminergic control of male sex behavior in rats: effects of an intracerebrally-infused agonist. Brain Res 1986, 370:73-81.
15. Melis M.R., Argiolas A., Gessa G.L. Apomorphine-induced penile erection and yawning: site of action in the brain. Brain Res 1987, 415:98-104.
16. Eaton R.G., Markowski V.F., Lumley L.A., Thompson J.T., Moses J., Hull E.M. D2 receptors in the paraventricular nucleus regulate genital responses and copulation in male rats. Pharmacol Biochem Behav 1991, 39:177-181.
17. Chen K.K., Chan J.Y.H., Chang L.S. Dopaminergic neurotransmission at the paraventricular nucleus of the hypothalamus in central regulation of penile erection in the rat. J Urol 1999, 162:237-242.
18. Giuliano F., Rampin O. Central neural control of penile erection. Neurosci Biobehav Rev 2000, 24:517-533.
19. Argiolas A., Melis M.R. Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Prog Neurobiol 1995, 47:235-255.
20. Baskerville T.A., Douglas A.J. Interaction between dopamine and oxytocin in the control of sexual behaviour. Prog Brain Res 2008, 170:277-289.
21. Baskerville T.A., Allard J., Wayman C., Douglas A.J. Dopamine-oxytocin interactions in penile erection. Eur J Neurosci 2009, 30:2151-2164.
22. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994, 15:264-270.
23. Sokoloff P., Schwartz J.C. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995, 16:270-275.
24. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
25. Brioni J.D., Moreland R.B., Cowart M., Hsieh G.C., Stewart A.O., Hedlund P., et al. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci USA 2004, 101:6758-6763.
26. Hsieh G.C., Hollingsworth P.R., Martino B., Chang R., Terranova M.A., O'Neill A.B., et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther 2004, 308:330-338.
27. Osinski M.A., Uchic M.E., Seifert T., Shaughnessy T.K., Miller L.N., Natane M., et al. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav 2005, 81:211-219.
28. Glase S.A., Akunne H.C., Georgic L.M., Heffner T.G., MacKenzie R.G., Manley P.J., et al. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. J Med Chem 1997, 40:1771-1772.
29. Enguehard-Gueiffier C., Hubner H., El Hakmaoui A., Allouchi H., Gmeiner P., Argiolas A., et al. 2-[(4-Phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J Med Chem 2006, 49:3938-3947.
30. Moreland R.B., Patel M., Hsieh G.C., Wetter J.M., Marsh K., Brioni J.D. A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav 2005, 82:140-147.
31. Lober S., Tschammer N., Hubner H., Melis M.R., Argiolas A., Gmeiner P. The azulene framework as a novel arene bioisostere: design of potent dopamine D4 receptor ligands inducing penile erection. ChemMedChem 2009, 4:325-328.
32. Melis M.R., Succu S., Mascia M.S., Argiolas A. PD 168,077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats. Neurosci Lett 2005, 379:59-62.
33. Melis M.R., Succu S., Sanna F., Melis T., Mascia M.S., Enguehard-Gueiffier C., et al. PIP3EA and PD 168,077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain. Eur J Neurosci 2006, 24:2021-2030.
34. Collins G.T., Truccone A., Haji-Abdi F., Newman A.H., Grundt P., Rice K.C., et al. Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther 2009, 329:210-217.
35. Depoortère R., Bardin L., Rodrigues M., Abrial E., Allaga M., Newman-Tancredi A. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. Behav Pharmacol 2009, 20:303-311.
36. Ferrari F., Pelloni F., Giuliani D. Behavioral evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND919, a new selective D2 dopamine receptor agonist. Psychopharmacology 1993, 113:172-176.
37. Bennett J.P., Piercey M.F. Pramipexole-a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999, 163:25-31.
38. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2004, Academic Press, New York. 4th edn.
39. Succu S., Sanna F., Melis T., Boi A., Argiolas A., Melis M.R. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: involvement of central oxytocin. Neuropharmacology 2007, 52:1034-1043.
40. Kulagowski J.J., Broughton H.B., Curtis N.R., Mawer I.M., Ridgill M.P., Baker R., et al. 3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem 1996, 39:1941-1942.
41. Stemp G., Ashmeade T., Branch C.L., Hadley M.S., Hunter A.J., Johnson C.N., et al. Design and synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 2000, 43:1878-1885.
42. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011A. J Pharmacol Exp Ther 2000, 294:1154-1165.
43. Bettinetti L., Schlotter K., Hubner H., Gmeiner P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J Med Chem 2002, 45:4594-4597.
44. Patel S., Freedman S., Chapman K.L., Emms F., Fletcher A.E., Knowles M., et al. Biological profile of L 745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther 1997, 283:636-647.
45. Millan M.J., Newman-Tancredi A., Brocco M., Gobert A., Lejeune F., Audinot V., et al. S 18126 ([2-[4-(2,3-dihydrobenzo [1,4] dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J Pharmacol Exp Ther 1998, 287:167-186.
46. Millan M.J., Dekeyne A., Rivet J.M., Dubuffet T., Lavielle G., Brocco M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: II. Functional and behavioral profile compared with GR218,231 and L 741, 626. J Pharmacol Exp Ther 2000, 293:1063-1073.
47. Millan M.J., Di Cara B., Dekeyne A., Panayi F., De Groote L., Sicard D., et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007, 100:1047-1061.
48. Mierau J., Schneider F.J., Ensinger H.A., Chio C.L., Lajiness M.E., Huff R.M. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995, 290:29-36.
49. Chio C.L., Laijness M.E., Ruff M.R. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 1994, 45:51-60.
50. Newmann-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De Ceuninck F., Boutin J.A., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor. J Pharmacol Exp Ther 2002, 303:805-814.
51. Hall D.A., Strange P.G. Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese Hamster Ovary (CHO) cells. Biochem Pharmacol 1999, 58:285-289.
52. Moreland R.B., Nakane M., Donnelly-Roberts D.L., Miller L.N., Chang R., Uchic M.E., et al. Comparative pharmacology of human dopamine D2-like receptor stable cell lines coupled to calcium flux through Gαqo5. Biochem Pharmacol 2004, 68:761-772.